Knee osteoarthritis (OA) is one of the major causes of disability throughout the world. OA was designated as the fourth leading cause of years lived with disability at global level reporting for 3.0% of total global years lived with disability (YLDs) in 2000 according to the World Health Report. The loss of hyaluronan in the synovial fluid and cartilage of the knee cause joint pain and stiffness in knee OA patients.
HA CW et al. executed a randomized, multi-center, double-blind, non-inferiority study to investigate the efficacy and safety of a cross-linked hyaluronate (XLHA, single injection form) distinguished with a linear high molecular hyaluronate (HMWHA, thrice injection form) in symptomatic knee osteoarthritis patients.